Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Clinically significant outcomes (CSOs) connect patient-reported outcome measures data to patient-perceived benefit. Although investigators have established threshold values for various CSOs, the timeline to achieve these outcomes after isolated biceps tenodesis (BT) has yet to be defined.

Purpose: To define the time-dependent nature of minimal clinically important difference (MCID), substantial clinical benefit (SCB), and Patient Acceptable Symptom State (PASS) achievement after isolated BT.

Study Design: Case series; Level of evidence, 4.

Methods: The American Shoulder and Elbow Surgeons score (ASES), the Single Assessment Numeric Evaluation, and the Constant-Murley score (CMS) were administered preoperatively and at 6 and 12 months postoperatively to patients undergoing isolated BT between 2014 and 2018 at our institution. Cumulative probabilities for achieving MCID, SCB, and PASS were calculated using Kaplan-Meier survival analysis. Weibull parametric regression evaluated the hazard ratios (HRs) of achieving earlier MCID, SCB, and PASS.

Results: Overall cohort (N = 190) achievement rates ranged between 77.8% and 83.2% for MCID, between 42.2% and 80.2% for SCB, and between 59.7% and 62.9% for PASS. Median achievement time was 5.3 to 6.1 months for MCID, 5.9 to 6.4 months for SCB, and 6.07 to 6.1 months for PASS. Multivariate Weibull parametric regression identified older age, male sex, higher body mass index, preoperative thyroid disease, smoking history, and higher preoperative CMS as predictors of delayed CSO achievement (HR, 1.01-6.41), whereas normal tendon on arthroscopy, defined as absence of tenosynovitis or tendon tear on arthroscopy, predicted earlier CSO achievement (HR, 0.19-0.46). Location of tenodesis and worker compensation status did not significantly predict the time to achieve CSOs on multivariate analysis.

Conclusion: After isolated BT, patients can expect to attain CSO by 13 months postoperatively, with most patients achieving this between 5 and 8 months. Patients tend to take longer to achieve PASS than MCID and SCB.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908395PMC
http://dx.doi.org/10.1177/23259671221070857DOI Listing

Publication Analysis

Top Keywords

mcid scb
12
clinically outcomes
8
outcomes isolated
8
isolated biceps
8
months postoperatively
8
postoperatively patients
8
weibull parametric
8
parametric regression
8
cso achievement
8
mcid
6

Similar Publications

Introduction: The NarxCare Overdose Risk Score (ORS) is a measure of prescription drug use with scores ranging from 0 to 999, and higher scores suggest worse prescription drug use patterns, including opioids, sedatives, and stimulants. We aimed to evaluate the association of preoperative NarxCare ORS with clinically meaningful improvements in patient-reported outcome measures (PROMs) and satisfaction at one year.

Methods: Patients undergoing primary total knee arthroplasty (TKA) at an academic healthcare system (November 2018 to December 2022) were included.

View Article and Find Full Text PDF

Background: Improvements in patient-reported outcome measure (PROM) scores have been widely documented after posterior cruciate ligament reconstruction (PCLR). Establishing clinically significant outcome (CSO) benchmarks for PROMs can enhance their clinical applicability.

Purpose: To establish the minimal clinically important difference (MCID), substantial clinical benefit (SCB), and patient acceptable symptomatic state (PASS) for PROMs after primary PCLR and identify the predictors of achieving them.

View Article and Find Full Text PDF

Using Percentage of Maximal Possible Improvement (MPI) to Predict High Patient Satisfaction Following the Latarjet Procedure.

J Shoulder Elbow Surg

August 2025

Division of Shoulder and Elbow Surgery, Department of Orthopedic Surgery, NYU Grossman School of Medicine, NYU Langone Orthopedic Hospital, NYU Langone Health, New York, NY, USA. Electronic address:

Background: Outcome thresholds such as the minimal clinically important difference (MCID), patient acceptable symptomatic state (PASS), and substantial clinical benefit (SCB) are commonly used to define meaningful clinical improvement. However, these measures apply uniform cutoffs that do not account for individual baseline scores. Maximal Possible Improvement (MPI) offers a patient-specific approach by considering the maximal potential gain in function or reduction in pain.

View Article and Find Full Text PDF

Purpose: This study aims to define the minimal clinically important difference (MCID) and substantial clinical benefit (SCB) for EQ-5D-5 L and identify factors associated with clinical benefit achievement after Full Endoscopic Spine Surgery (FESS).

Methods: This is a retrospective analysis of a multicentric prospective study that included adults who underwent FESS for lumbar degenerative spine disease. Patients were monitored postoperatively via a smartphone application, PROMs including EQ-5D-5 L and Oswestry Disability Index (ODI), were collected preoperatively and one-year postoperatively.

View Article and Find Full Text PDF

Background: There is a limited literature available describing the various diagnostic modalities and treatment options for the management of subspine impingement (SSI). We developed a study to evaluate the clinical improvement at 1 year and 5 years, with iHOT 33 and HOS hip scores.

Questions: (1) Do patients with subspine compression improve with arthroscopic treatment clinically at short-term follow-up (1 year); (2) Is the improvement maintained in the mid-term (5 years)?

Methods: 43 young patients (21-65 years) with subspine compression (prominent anterior inferior iliac spine) treated arthroscopically between January 2010 and December 2021 were included.

View Article and Find Full Text PDF